Influence of Obesity on Propofol Pharmacokinetics During Cardiopulmonary Bypass

NCT ID: NCT02477982

Last Updated: 2015-06-23

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 34 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2012-12-31
• Study Completion Date: 2014-08-31

Brief Summary

The primary objective of this study is to develop a descriptive and predictive pharmacokinetics model propofol disposition during cardiopulmonary bypass (CPB) in obese and lean patients.

Detailed Description

Anaesthesia maintenance upon initiation of CPB will be achieved by propofol (1%) bolus (1 mg/kg TBW) immediately followed by 2 mg/kg TBW/hr infusion that will be continued till weaning from CPB. During CPB an additional propofol bolus doses can be administered to prevent awareness according to the clinical judgment of the responsible anaesthesiologist. Any additional doses given and their timings will be recorded.

Blood samples of 2 ml each will be collected from the arterial line of CPB machine until the end of CPB then from sub-clavin arterial catheter routinely inserted in such surgeries. Sampling process will follow the following schedule; at baseline prior to dosing, followed by samples at 1, 3, 5,7 min after the propofol bolus dose, then every 20 minutes during propofol infusion, just before discontinuation of the propofol infusion and at 1, 3, 5, 7, 10, 20, 30, 60 minutes after the end of infusion. In addition, just before any rescue propofol dose administration, an unscheduled sample will be withdrawn

Conditions

Obesity

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

control group

BMI ≤ 25 kgm-2

No interventions assigned to this group

obese group

BMI ≥ 30 kgm-2

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• BMI ≤ 25 kg/m2 or ≥ 30 kg/m2.
• Propofol based maintenance of anaesthesia during CPB.

Exclusion Criteria

• Pregnant women or lactating mothers.
• Renal (serum creatinine concentration>1.5 or creatinine Cl ≤ 30 ml/min) or hepatic disorders (total bilirubin >1.5 or ≥ 2 fold increase in alanine transferase (ALT) or aspartate transferase (AST).
• Systemic infections.
• Hypoalbuminemia (defined as albumin <3.5 gm/dL).
• Known history of alcohol or drug abuse.
• Administration of aspirin on the day of surgery or warfarin within 7 days preceding surgery

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cairo University

OTHER

Sponsor Role: lead

Responsible Party

Eman Ali Ali

Teaching assistant at clinical pharmacy department faculty of pharmacy

Responsibility Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

CL(609)

Identifier Type: -

Identifier Source: org_study_id